Targets › PSCA
4 programs from 4 companies in 7 trials: 7 Phase 1; Oncology; next expected readout Mar 2027.
May be involved in the regulation of cell proliferation. Has a cell-proliferation inhibition activity in vitro..; FUNCTION: May act as a modulator of nicotinic acetylcholine receptors (nAChRs) activity. (UniProt, O43653)
Open in Phaseline: the race on PSCA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Beijing Biotech | ETB-DualNK-01 Dual-target anti-PSMA/PSCA CAR-NK cells | PSMA, PSCA | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Mar 2027 |
| City of Hope Medical Center | Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes Anti-PSCA CAR-T cell therapy targeting PSCA+ tumor cells | PSCA | Phase 1 | Castration-Resistant Prostate Carcinoma | Mar 2027 |
| Amgen | AMG 509 PSCA-directed chimeric costimulatory receptor T cell therapy | PSCA | Phase 1 | Extensive Stage Small Cell Lung Cancer; Prostate Cancer; Small Cell Lung Cancer | Mar 2028 |
| Regeneron Pharmaceuticals | BPX-601 Anti-PSCA CAR-T cell therapy | PSCA | Phase 1 | Prostate Cancer | Feb 2030 |
Prostate Cancer (2) Castration-Resistant Prostate Carcinoma (2) Extensive Stage Small Cell Lung Cancer (1) Small Cell Lung Cancer (1) Metastatic Castration-resistant Prostate Cancer (1)
mixed (3), other (1)
Amgen (1) City of Hope Medical Center (1) Regeneron Pharmaceuticals (1) Beijing Biotech (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.